{"id":"rosiglitazone-metformin","safety":{"commonSideEffects":[{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Fluid retention / edema"},{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disturbance (nausea, diarrhea)"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL121","moleculeType":"Small molecule","molecularWeight":"357.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rosiglitazone is a PPAR-γ agonist that enhances insulin sensitivity in muscle and adipose tissue by promoting glucose uptake and reducing insulin resistance. Metformin is a biguanide that decreases hepatic glucose production and improves insulin-mediated glucose uptake in peripheral tissues. Together, they provide complementary mechanisms to lower blood glucose in type 2 diabetes.","oneSentence":"This combination drug improves insulin sensitivity through a thiazolidinedione (rosiglitazone) that activates PPAR-γ and metformin that reduces hepatic glucose production and improves peripheral insulin sensitivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:57.281Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT04114136","phase":"PHASE2","title":"Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2020-09-14","conditions":"Melanoma, NSCLC, Hepatocellular Carcinoma","enrollment":72},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT00081328","phase":"PHASE3","title":"Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2004-05","conditions":"Diabetes Mellitus, Type II","enrollment":699},{"nctId":"NCT04148183","phase":"PHASE2, PHASE3","title":"Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients.","status":"COMPLETED","sponsor":"J JESUS VENEGAS, MD","startDate":"2004-01-01","conditions":"Insulin Resistance","enrollment":30},{"nctId":"NCT00481429","phase":"","title":"Predictive Markers of Glitazone Efficacy in Diabetic Patients - Pilot Study","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2007-05","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT00427154","phase":"PHASE3","title":"Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2007-01-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":227},{"nctId":"NCT00577590","phase":"NA","title":"Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2003-10","conditions":"Diabetes Mellitus, Type II","enrollment":78},{"nctId":"NCT00679939","phase":"PHASE4","title":"Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-21","conditions":"Diabetes Mellitus, Type 2","enrollment":226},{"nctId":"NCT00499707","phase":"PHASE3","title":"Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10-08","conditions":"Diabetes Mellitus, Type 2","enrollment":453},{"nctId":"NCT00241605","phase":"PHASE4","title":"AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-06-25","conditions":"Diabetes Mellitus, Type 2","enrollment":600},{"nctId":"NCT00067951","phase":"PHASE3","title":"A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10-17","conditions":"Diabetes Mellitus, Type 2","enrollment":190},{"nctId":"NCT00279045","phase":"PHASE3","title":"Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-01-03","conditions":"Diabetes Mellitus, Type 2","enrollment":4426},{"nctId":"NCT00501020","phase":"PHASE4","title":"Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-06-05","conditions":"Diabetes Mellitus, Type 2","enrollment":750},{"nctId":"NCT00948324","phase":"PHASE4","title":"Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes","status":"SUSPENDED","sponsor":"Sun Yat-sen University","startDate":"2008-06","conditions":"Type 2 Diabetes Mellitus","enrollment":400},{"nctId":"NCT01332071","phase":"PHASE1","title":"Avandamet Bioequivalence Study Brazil - Fed Administration","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-24","conditions":"Diabetes Mellitus, Type 2","enrollment":26},{"nctId":"NCT01294553","phase":"","title":"An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVANDAMET Between June 2004 and January 2010","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-06","conditions":"Diabetes Mellitus, Type 2","enrollment":717},{"nctId":"NCT01332370","phase":"","title":"Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-12","conditions":"Diabetes Mellitus, Type 2","enrollment":5391},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00350779","phase":"PHASE3","title":"Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06-12","conditions":"Type 2 Diabetes Mellitus","enrollment":262},{"nctId":"NCT00481663","phase":"PHASE2","title":"A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-08-19","conditions":"Type II Diabetes Mellitus","enrollment":555},{"nctId":"NCT00032487","phase":"PHASE3","title":"Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2000-12-01","conditions":"Type 2 Diabetes Mellitus","enrollment":1791},{"nctId":"NCT00379769","phase":"PHASE3","title":"RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-04","conditions":"Diabetes Mellitus, Type 2","enrollment":4447},{"nctId":"NCT00348712","phase":"PHASE3","title":"Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2006-10-30","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":301},{"nctId":"NCT00402909","phase":"PHASE4","title":"Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-11","conditions":"Type 2 Diabetes","enrollment":28},{"nctId":"NCT00399711","phase":"PHASE3","title":"Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":560},{"nctId":"NCT00333151","phase":"PHASE3","title":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":576},{"nctId":"NCT00386100","phase":"PHASE4","title":"A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":688},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00396227","phase":"PHASE3","title":"Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":2665},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT00975286","phase":"PHASE3","title":"24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":446},{"nctId":"NCT00484419","phase":"PHASE3","title":"Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-05","conditions":"Type 2 Diabetes, Hyperlipidemia","enrollment":169},{"nctId":"NCT00069836","phase":"PHASE3","title":"Study Of AVANDAMET® With Or Without Insulin In Type II Diabetes Mellitus Patients. AVANDAMET® is a Registered Trademark of the GSK Group of Companies.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Diabetes Mellitus, Type 2","enrollment":272},{"nctId":"NCT00437970","phase":"PHASE4","title":"Medication in Early Diabetes (MED) Study","status":"WITHDRAWN","sponsor":"Menzies School of Health Research","startDate":"2008-04","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT00933309","phase":"PHASE1","title":"The Impact of Obesity and Obesity Treatments on Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-07","conditions":"Breast Cancer","enrollment":25},{"nctId":"NCT00486187","phase":"NA","title":"Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study","status":"COMPLETED","sponsor":"Dr. Milan Gupta","startDate":"2006-04","conditions":"Type 2 Diabetes Mellitus","enrollment":103},{"nctId":"NCT00541775","phase":"PHASE3","title":"Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06","conditions":"Type 2 Diabetes Mellitus","enrollment":273},{"nctId":"NCT02526615","phase":"PHASE4","title":"Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes","status":"COMPLETED","sponsor":"Turku University Hospital","startDate":"2000-10","conditions":"Insulin Sensitivity, Type 2 Diabetes","enrollment":48},{"nctId":"NCT00135330","phase":"PHASE3","title":"An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-10","conditions":"Diabetes Mellitus, Type 2","enrollment":137},{"nctId":"NCT00295633","phase":"PHASE3","title":"A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-03","conditions":"Diabetes Mellitus, Type 2","enrollment":565},{"nctId":"NCT00618072","phase":"PHASE2","title":"EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2008-01","conditions":"Hyperinsulinemia, Insulin Resistance, Obesity","enrollment":46},{"nctId":"NCT01195259","phase":"","title":"Malignancy Meta Analysis for BRL49653","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10","conditions":"Diabetes Mellitus, Type 2","enrollment":1},{"nctId":"NCT00680745","phase":"PHASE3","title":"Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":597},{"nctId":"NCT00015691","phase":"NA","title":"Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Lipodystrophy, Hyperinsulinemia","enrollment":105},{"nctId":"NCT00131664","phase":"PHASE3","title":"Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)","status":"COMPLETED","sponsor":"Canadian Heart Research Centre","startDate":"2005-09","conditions":"Type 2 Diabetes Mellitus","enrollment":391},{"nctId":"NCT00636766","phase":"NA","title":"Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2005-09","conditions":"Carotid Atherosclerosis, Stroke, Type 2 Diabetes","enrollment":300},{"nctId":"NCT00373178","phase":"PHASE4","title":"Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2005-01","conditions":"Type 2 Diabetes Mellitus","enrollment":100},{"nctId":"NCT00116922","phase":"PHASE3","title":"A Lifestyle and Combination Medication Therapy Diabetes Prevention Study","status":"COMPLETED","sponsor":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","startDate":"2004-06","conditions":"Impaired Glucose Tolerance, Diabetes","enrollment":207},{"nctId":"NCT00343395","phase":"PHASE4","title":"Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot Study","status":"TERMINATED","sponsor":"Intermountain Health Care, Inc.","startDate":"2006-06","conditions":"Coronary Artery Disease","enrollment":200},{"nctId":"NCT00358124","phase":"PHASE4","title":"Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-01","conditions":"Type 2 Diabetes Mellitus","enrollment":220},{"nctId":"NCT00367055","phase":"PHASE4","title":"Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10","conditions":"Type 2 Diabetes Mellitus","enrollment":84},{"nctId":"NCT00699036","phase":"PHASE2","title":"Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)","status":"UNKNOWN","sponsor":"Brooke Army Medical Center","startDate":"2007-04","conditions":"Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease","enrollment":165},{"nctId":"NCT00359112","phase":"PHASE3","title":"AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-02","conditions":"Non-Insulin-Dependent Diabetes Mellitus","enrollment":544},{"nctId":"NCT00318656","phase":"PHASE4","title":"24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11","conditions":"Non-Insulin-Dependent Diabetes Mellitus","enrollment":23},{"nctId":"NCT00203632","phase":"PHASE3","title":"Glitazones and Endothelial Function (GATE)","status":"TERMINATED","sponsor":"University of Calgary","startDate":"2003-09","conditions":"Diabetes Mellitus","enrollment":40},{"nctId":"NCT00150410","phase":"PHASE3","title":"Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-01","conditions":"Diabetes Mellitus","enrollment":626},{"nctId":"NCT00776607","phase":"NA","title":"Randomized Controlled Trial of Insulin Versus Tablets for Latent Autoimmune Diabetes in Adults (LADA)","status":"UNKNOWN","sponsor":"Abertawe Bro Morgannwg University NHS Trust","startDate":"2007-04","conditions":"Latent Autoimmune Diabetes in Adults LADA","enrollment":200},{"nctId":"NCT00282945","phase":"NA","title":"Beta Cell Function Tests Over Time In Patients With T2dm Randomized To Metformin Or Rosiglitazone","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-01","conditions":"Type 2 Diabetes Mellitus","enrollment":29},{"nctId":"NCT00361868","phase":"PHASE3","title":"Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI","status":"TERMINATED","sponsor":"Solvay Pharmaceuticals","startDate":"2006-06","conditions":"Dyslipidemia, Glucose Metabolism Disorder","enrollment":88},{"nctId":"NCT00121966","phase":"PHASE4","title":"South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2003-01","conditions":"Type 2 Diabetes Mellitus","enrollment":400},{"nctId":"NCT00110851","phase":"PHASE2","title":"Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)","status":"COMPLETED","sponsor":"Wellstat Therapeutics","startDate":"2005-04","conditions":"Type 2 Diabetes Mellitus","enrollment":90},{"nctId":"NCT00483392","phase":"NA","title":"Treatment of Hyperglycaemia and Insulin Resistance in HIV Infected Patients","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"","conditions":"Insulin Resistance","enrollment":""},{"nctId":"NCT00015626","phase":"PHASE2","title":"A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"","conditions":"Insulin Resistance, Diabetes Mellitus","enrollment":300}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"CARDIAC ARREST"},{"count":6,"reaction":"HEAT STROKE"},{"count":4,"reaction":"MYOCARDIAL INFARCTION"},{"count":4,"reaction":"UNRESPONSIVE TO STIMULI"},{"count":3,"reaction":"BUNDLE BRANCH BLOCK RIGHT"},{"count":3,"reaction":"DYSPNOEA"},{"count":3,"reaction":"HYPERTHERMIA"},{"count":3,"reaction":"METABOLIC ACIDOSIS"},{"count":3,"reaction":"RENAL FAILURE ACUTE"},{"count":3,"reaction":"SUPRAVENTRICULAR TACHYCARDIA"}],"_approvalHistory":[],"publicationCount":64,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"rosiglitazone-metformin","genericName":"rosiglitazone-metformin","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug improves insulin sensitivity through a thiazolidinedione (rosiglitazone) that activates PPAR-γ and metformin that reduces hepatic glucose production and improves peripheral insulin sensitivity. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}